Geode Capital Management, LLC Biovie Inc. Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Biovie Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 247,106 shares of BIVI stock, worth $111,197. This represents 0.0% of its overall portfolio holdings.

Number of Shares

247,106

Previous 187,589 31.73%

Holding current value

$111,197

Previous $236,000 44.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.53 - $1.89 $31,544 - $112,487	59,517 Added 31.73%	247,106 $130,000
Q4 2023 Feb 13, 2024	BUY	$1.22 - $5.24 $59,993 - $257,677	49,175 Added 35.53%	187,589 $236,000
Q3 2023 Nov 13, 2023	SELL	$2.75 - $5.17 $35,917 - $67,525	-13,061 Reduced 8.62%	138,414 $471,000
Q2 2023 Aug 11, 2023	BUY	$4.09 - $8.29 $127,910 - $259,261	31,274 Added 26.02%	151,475 $652,000
Q1 2023 May 15, 2023	BUY	$4.89 - $10.53 $213,257 - $459,223	43,611 Added 56.94%	120,201 $971,000

Q4 2022 Feb 13, 2023	BUY	$3.86 - $13.38 $143,406 - $497,093	37,152 Added 94.2%	76,590 $595,000
Q2 2022 Aug 12, 2022	BUY	$1.44 - $5.04 $7,273 - $25,457	5,051 Added 14.69%	39,438 $57,000
Q1 2022 May 13, 2022	BUY	$2.74 - $5.65 $16,492 - $34,007	6,019 Added 21.22%	34,387 $162,000
Q4 2021 Feb 11, 2022	BUY	$4.41 - $6.99 $41,520 - $65,810	9,415 Added 49.68%	28,368 $127,000
Q3 2021 Nov 12, 2021	SELL	$6.69 - $16.93 $26,392 - $66,788	-3,945 Reduced 17.23%	18,953 $127,000
Q2 2021 Aug 13, 2021	BUY	$10.57 - $21.61 $17,947 - $36,693	1,698 Added 8.01%	22,898 $388,000
Q1 2021 May 12, 2021	BUY	$14.35 - $44.81 $304,220 - $949,972	21,200 New	21,200 $410,000

Others Institutions Holding BIVI

# of Institutions

Shares Held

Call Options Held

51.7K

Put Options Held

353K

View Full List

About BIOVIE INC.

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $13.6M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

More about BIVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Biovie Inc. Transaction History